Evidence map›Paper›PMID 35501077›Full record

ArticleBMJ open2022

Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients.

Diana Rofail, Nadine McGale, Anna J Podolanczuk, Alissa Rams, Krystian Przydzial, Sumathi Sivapalasingam, Vera Mastey, Patrick Marquis

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Diana RofailRegeneron Pharmaceuticals Inc, Sleepy Hollow, New York, USA diana.rofail@regeneron.com.ORCID 0000-0002-2125-4734
Nadine McGaleModus Outcomes, Letchworth Garden City, UK.
Anna J PodolanczukWeill Cornell Medical College, New York, New York, USA.
Alissa RamsModus Outcomes, Letchworth Garden City, UK.
Krystian PrzydzialModus Outcomes, Letchworth Garden City, UK.
Sumathi SivapalasingamRegeneron Pharmaceuticals Inc, Sleepy Hollow, New York, USA.
Vera MasteyRegeneron Pharmaceuticals Inc, Sleepy Hollow, New York, USA.
Patrick MarquisModus Outcomes, Letchworth Garden City, UK.
Regeneron (United States) · USCornell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThere is little in-depth qualitative evidence of how symptoms manifest themselves in outpatients with COVID-19 and how these in turn impact outpatients' daily lives. The objective of the study was therefore to explore the experience of outpatients with COVID-19 qualitatively, concerning the symptomatic experience and its subsequent impact on daily life.

settingQualitative research study comprising virtual in-depth, open-ended interviews with outpatients and clinicians.

participantsThirty US adult patients with COVID-19 were interviewed within 21 days of diagnosis. Patients were 60% female and 87% white, who had to self-report one of the following: fever, cough, shortness of breath/difficulty breathing, change/loss of taste/smell, vomiting/diarrhoea or body/muscle aches. Five independent clinicians were also interviewed about their experience treating outpatients. PRIMARY AND SECONDARY OUTCOME MEASURES: Transcripts were analysed thematically to organise symptoms and impacts of daily life into higher-order overarching categories, and subsequently propose a conceptual model. The adequacy of the sample size was assessed by conceptual saturation analysis.

resultsPatient-reported concepts were organised into six symptom themes (upper respiratory, lower respiratory, systemic, gastrointestinal, smell and taste, and other) and seven impact themes (activities of daily living, broad daily activities, leisure/social activities, and physical, emotional, professional and quarantine-specific impacts). Symptom type, severity, duration and time of onset varied by patient. Clinicians endorsed all patient-reported symptoms.

conclusionsThe manifestation of symptoms in outpatients is heterogeneous and affects all aspects of daily life. Outpatients offered new detailed insights into their symptomatic experiences, including heterogeneous experiences of smell and taste, and the impacts that symptoms had on their daily lives. Findings of this research may be used to supplement existing knowledge of the outpatient experience of mild-to-moderate COVID-19, to further inform treatment guidelines and to provide an evidence base for evaluating potential treatment benefits.

Indexed as

COVID-19OutpatientsActivities of Daily LivingAdultDyspneaFemaleHumansMalePatient Outcome AssessmentQualitative ResearchCOVID-19INFECTIOUS DISEASESQUALITATIVE RESEARCHVIROLOGY

Identifiers

PMID35501077
PMCPMC9062460
OpenAlexW4225289831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.